Dr. Tesha Monteith and Dr. Patricia Pozo-Rosich discuss the latest advancements in headache medicine, focusing on key research findings from 2025. Show transcript: Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. Welcome to our 2026 Headache Medicine Series. I've just been speaking with Patricia Pozo-Rosich about all of the exciting advances in headache medicine in 2025. For a minute, why don't you summarize some of the key advances in headache medicine research? Dr. Patricia Pozo-Rosich: I think that we have good news in headache. We are currently phase two trials for two or three different compounds, anti-part two, packup and new toxins. So we are actually, I think, excited to find out the phase 2B trial results and phase three. So well, that's something that I think is worth mentioning. Then I think it is important to remember that we have new data coming from real world evidence with long-term use of anti CGRP therapies. We also have data that shows that anti CGRP therapies are useful for patients with migraine and major depressive disorder, as well as as children. Finally, I think that it is very important to remind everyone that there are new papers on practice recommendations around the world on how we have to treat our patients with migraine, and that is related both to the acute and preventive therapies. And finally, couple of position statements that have been written by the International Hague Society that strive to improve the quality of how migraine individuals are treated, and that really conveys a paradigm shift where we probably should be starting preventive therapy sooner than later. Dr. Tesha Monteith: Great. Thank you so much for that quick summary. And please check out the Full Headache Medicine series. I appreciate talking to you, Patricia, and look forward to discussing more highlights next time. Dr. Patricia Pozo-Rosich: Thank you, Tisha. See you very soon. Dr. Tesha Monteith: And thank you for listening to the Neurology Minutes.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related